IPF why wait?
IPF is a progressive and life threatening lung disease that can cause permanent damage in the lungs right from the start. Early diagnosis and treatment of IPF is critical, because acting quickly can make a difference.
Search
Solid Fundations | Bioxcellence | Boehringer Ingelheim
Discover BioXcellence's innovative biopharmaceutical contract manufacturing services, built on a proven track record & solid foundation. Explore now!
biopharmaceuticals-in-china
Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.
Major investment for respiratory diseases completed
105 million euros invested into expansion of production facilities in Ingelheim and Dortmund
cystic fibrosis phase II trial
The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
Digital Therapeutic
Digital Therapeutic
Our Purpose
Why we exist
Metacam®
For the treatment of mastitis in lactating cows and for the control of pain associated with dehorning or surgery.
Eyes on Retina. The Podcast
Hear from experts and people living with retinal diseases such as wet age-related macular degeneration (AMD), stargardt disease and diabetic retinopathy.
EHS management approach
We protect our employees, facilities and the environment from harmful influences, conserve natural resources and promote environmental awareness
InSensitive Content: impact on the GPP patient community
Understand why the patient community should be able to post and consume visual content related to generalized pustular psoriasis.
Global language learning platform for our people
One global learning platform for languages, countless opportunities to grow your career
George Okafo
My career challenge at Boehringer Ingelheim by George Okafo. Read it now!
Smart scanners to spot fleas and ticks on your pet
How to identify fleas and ticks? With technology, vets can now spot pet parasites with high-definition videos in real time.
Expectations towards our business partners
We utilize an extensive network of international suppliers for procuring raw materials, intermediates, packaging materials, technical components and services to deliver our innovative medications worldwide.
REACH / GHS / Material safety data sheets
We are continuously working on these topics with the aim to be in compliance with requirements deriving from these legislations.
Dogs at work in Milan offices
Dogs at work is a pilot project that allows pet-lover to bring their dogs to the office and enjoy the benefits they bring to their daily work life.
Scam alert
A recruitment scam involving Boehringer Ingelheim is circulating.
Biopharmaceuticals: large molecules, enormous potential
Researching, developing and manufacturing biopharmaceuticals is a highly complex and lengthy process, but it has enormous potential.
2020-Positive-business-momentum-despite-COVID-19-impact
While stepping up its investments in R&D significantly, Boehringer Ingelheim achieved a solid business performance in 2020 despite the COVID-19 pandemic.
Iclepertin
Iclepertin: GlyT1 inhibitor
CT-155
Digital therapeutic
Working with purpose
Colleagues tell their personal stories and what motivates them to contribute towards a better future for generations to come.
Animal Welfare through environmental sustainability
Producing honey and contributing to environmental sustainability during your work hours.
Partnership for new liver disease treatments with Ribo
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases